ArticleNature communications2026

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.

Yonina R Murciano-Goroff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.